Team

Denise Jen


  • Member of Taipei Bar Association
  • Member of New York State Bar Association
  • Contact: denisejen@lcs.com.tw


  • Harvard Law School (LL.M.)
  • National Taiwan University (LL.B.) 
  • National Taiwan University (B.B.A in Finance.)
  • Recognised as a Rising Star Partner by IFLR since 2022
  • Ranked on the Up-and-Coming List on Corporate M&A section by Chambers in 2023

Areas of Expertise

Mergers and Acquisitions, Cross-border Investment, Private Equity Fund, Capital Markets, Energy, General Corporate and Securities Laws, Biotech and Pharmaceutical Laws 

Track Record

  • Representation of TXOne Network in its multi-series preferred shares fund raising and corporate restructuring
  • Representation of Bora Pharmaceutical in the US$50M acquisition of Eden Biologics’ CDMO businesses and US$195M acquisition of 100% equity stake of TWi Pharmaceuticals
  • Representation of MagiCapital in the US$138M acquisition of Ili Technology (a 100% subsidiary of MediaTek)
  • Representation of Quaser Group (a Taiwan listed company) of its acquisition of Winbro Group (a US and UK company in aerospace industry) and obtain US CFIUS approval
  • Representation of TPG Group’s acquisition of OPC Group (the top one CRO company in Taiwan)
  • Representation of Guangdong Fenghua Advanced Technology (a Shenzhen listed company) in its tender offer of Viking Tech. (First tender offer deal of a Taiwan listed company by a PRC investor.)
  • Representation of CID -led consortium in its tender offer and merger of Entire Technology and APEC (both are Taiwan listed companies).
  • Representation of Bora Pharmaceutical’s acquisition of 100% shareholding in Impax Laboratories (a subsidiary of US Impax group) and various investment projects
  • Representation of JEAN Group (a Taiwan listed company) in its asset sale to BOE Group (a Chinese SOE)
  • Representation of Novartis in its transaction with GlaxoSmithKline (“GSK”) in the sale of Novartis’ non-influenza Vaccines business and acquisition of GSK’s oncology portfolio
  • Representation of overseas Taiwanese investment in acquisition of targets in Europe, America and Asia
  • Offshore PE fund formation in the form of limited partnership and segregated portfolio company (AI, real property, manufacturing, IOT industry and etc.) and subsequent fund investment 
  • Taiwan PE fund formation in the form of closed-end company and limited partnership (biotech, pharmaceutical, manufacturing, IT semiconductor, energy and etc.) and subsequent fund investment
  • Representation of Venture Capital companies in their investment and disposal of portfolio companies
  • Representation of pharmaceutical companies and biotech companies in their clinical trial, OEM, license agreement and co-development of pharmaceutical products with various business partners
  • Representation of foreign investors and domestic private equity firms in the formation of energy funds and subsequent investments in solar energy projects
  • Representation of IPO projects in Hong Kong Stock Exchange, Shanghai Stock Exchange and Taiwan Stock Exchange

Publications

  • M&A Taiwan section (Lexology Getting the Deal Through Market Intelligence)
  • Corporate M&A – Taiwan: Trends and Developments (Chambers Global Practice Guide)
  • Acquisition Finance Taiwan section (Lexology Getting the Deal Through)
  • Private Equity Taiwan section (Lexology in-depth) 
  • “Digit and Innovation: Intellectual Property Law Issues under the Open Banking Regime” (The Changing Fintech Laws by LCS Elites)
  • “The Legal Challenge from Sharing Economy to Sharing Finance” (Fintech Development and Laws by LCS Elites)
  • “The Prospect and Limitation of Fundraising Activities for Biotech Industries in Taiwan” (Legal Practice and Operation of Modern Businesses by LCS Elites)
  • "Negotiation of Cross-Border Brand Licensing" (Business Law Commentary by LCS Elites) 
  • "Merger and Acquisition of REITs" (Trust Association)
  • "Responsibilities of the trust enterprise, in its role as a trustee, acting as the proprietor of a building and recommendations" (Trust Association)
  • "Fairness Test on Corporate Director's Self-Dealing: An Analysis of the Case of Weinberger v. UOP and Further Issues" (Cross-Strait Law Review)